Document:

exv10w61

Exhibit 10.61

*** Text Omitted and Filed Separately

Confidential Treatment Requested

Under 17 C.F.R. §§ 200.80(b)(4)

and 240.24b-2

AMENDMENT TO THE PATENT PURCHASE AGREEMENT

(THE “AMENDMENT”)

     QUALCOMM Incorporated, a Delaware corporation (“Purchaser”), and Applied Micro Circuits
Corporation, a Delaware corporation (“Seller”) hereby agree to amend that certain Patent Purchase
Agreement made and entered into by and between Purchaser and Seller effective on July 11, 2008 (the
“Agreement”) as set forth below.

     Whereas, Purchaser and Seller previously entered into an amendment to the Agreement and desire
to supersede and replace in its entirety that amendment with the amendment set forth below, which
is to be effective as of July 11, 2008.

     Now, Therefore, for and in consideration of the mutual promises and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, Seller and Purchaser
hereto, intending to be legally bound, hereby agree as follows:

AMENDMENT:

1. Effect of this Amendment. This amendment shall supersede and replace in its entirety,
effective as of July 11, 2008, the prior amendment to the Agreement that was previously entered
into by Purchaser and Seller.

2. Section 5.3(e) of Main Body of Agreement. The last sentence of Section 5.3(e) of the
main body of the Agreement is hereby deleted and replaced with the following:

        “Subsequent to the filing by Seller of a redacted version of this Agreement with the SEC
that redacts or omits provisions in the Agreement agreed to by the Parties, Seller may disclose to
third parties those provisions of such redacted version of the Agreement that are publicly
available through the SEC’s EDGAR website; provided, however, that, in connection with any such
disclosure, Seller does not disclose any of the redacted or omitted provisions of such redacted
version of the Agreement.”

3. Section 2.1 of Schedule 2.5 to the Agreement. The last sentence of Section 2.1 of
Schedule 2.5 of the Agreement is hereby deleted and replaced with the following:

     “[...***...]”

 

			
	*	 	Confidential Treatment Requested

Purchaser and Seller Confidential

-1-

 

4. Subsection (ii) of Section 5.3 of Schedule 2.5 (Retained Rights) of the Agreement.
Subsection (ii) of Section 5.3 of Schedule 2.5 (Retained Rights) of the Agreement is hereby
deleted and replaced with the following:

     “(ii) [...***...]”

5. No Other Amendment or Modification. Except as expressly set forth in this Amendment,
the Agreement shall remain in full force and effect without modification. The terms and conditions
of this Amendment and the Agreement shall not be amended, modified, altered or supplemented other
than by a means of written instrument duly executed and delivered on behalf of Purchaser and
Seller.

IN WITNESS WHEREOF, Purchaser and Seller have caused this Amendment to be executed by their duly
authorized representatives to be effective as of July 11, 2008.

	 	 	 	 	 	 	 	 	 	 	 
	QUALCOMM Incorporated	 	 	 	Applied Micro Circuits Corporation	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Philip J. Fries, Jr.
 

	 	 	 	By:
	 	/s/ Cynthia J. Moreland
 

	 	  
	 
	Name: Philip J. Fries, Jr.	 	 	 	Name: Cynthia J. Moreland	 	 
	 
	Title: VP & Legal Counsel	 	 	 	Title:  VP, General Counsel	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	Date: 7/14/08	 	 	 	Date: 7/14/08	 	 

 

			
	*	 	Confidential Treatment Requested

Purchaser and Seller Confidential

-2-exv10w1

Exhibit 10.1

CONFIDENTIAL TREATMENT HAS BEEN REQUESTED FOR PORTIONS OF THIS EXHIBIT. THE CONFIDENTIAL PORTIONS HAVE BEEN REDACTED
AND ARE DENOTED BY A TRIPLE ASTERISK (***). THE CONFIDENTIAL PORTIONS HAVE BEEN SEPARATELY FILED
WITH THE SECURITIES AND EXCHANGE COMMISSION.

THIS FIRST AMENDMENT TO DISTRIBUTION AGREEMENT (the “First Amendment”) is entered into as of this
15th day of August, 2008 (the “Amendment Date”) by and between Amphastar
Pharmaceuticals, Inc., a Delaware Corporation, (“Amphastar”) and Andrx Pharmaceuticals, Inc. a
Florida Corporation, d/b/a Watson Laboratories — Florida (“Watson”).

WHEREAS, Amphastar and Watson have previously entered into that certain Distribution Agreement
dated May 2, 2005 (the “Agreement”) related to, among other things, Watson’s distribution of
Product (as defined in the Agreement); and

WHEREAS, the parties wish to amend the Agreement as set forth below;

NOW THEREFORE, in consideration of the mutual covenants and promises contained herein, and for
other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereby agree as follows:

1. Amendment of Section 3.1 and 3.2.2 of the Agreement.

(a) Section 3.1 of the Agreement is hereby deleted in its entirety and replaced with the
following:

“3.1 Milestones and Payments. In consideration of Seller’s grant of the exclusive
distribution rights hereunder to Purchaser, Purchaser shall pay Seller the sum of
$4,500,000 upon the Effective Date of this Agreement.”

(b) The fourth line of Section 3.2.2 of the Agreement is hereby amended by replacing “Section
3.1(a)” with “Section 3.1.”

2. Amendment of Sections 4.1.1 and 4.1.2 of the Agreement. 

(a) The fourth line of Section 4.1.1 of the Agreement is hereby amended by replacing [***] with
[***] The fifth line of Section 4.1.1 of the Agreement is hereby amended by replacing [***] with
[***].

(b) The first line of Section 4.1.2 is hereby amended by replacing “third anniversary” with “first
anniversary.”

3. Amendment of Section 4.2.1(a) of the Agreement. 

Section 4.2.1(a) of the Agreement is hereby amended by replacing “60%” with [***]

*** Certain confidential information contained in this document, marked with three asterisks, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

 

 

4. Amendment of Section 5.1 of the Agreement.

Section 5.1 of the Agreement is hereby deleted in its entirety and replaced with the following
section 5.1:

“5.1 Initial Purchase Order; Launch Quantities. Within ten (10) days of the Amendment
Date, Purchaser shall deliver to Seller an initial binding order (the “Initial Purchase
Order”) for [***] units of Product (the “Launch Quantities”) required for Purchaser’s
commercial launch of the Product consistent with Purchaser’s then current Forecast.
Subject to the terms of this Agreement , Seller shall supply the Launch Quantities to
Purchaser within [***] days of Seller’s receipt of final FDA approval of the Product ANDA.
Seller shall thereafter use Commercially Reasonable Efforts to supply Purchaser such
additional quantities of the Product as ordered by Purchaser hereunder pursuant to Section
5.3. All Launch Quantities shall have at least [***] of expiry dating remaining on such
Products at the time of delivery to Purchaser. In order to ensure adequate inventory to
timely deliver Purchaser’s anticipated needs for Launch Quantities, upon receipt of the
Initial Purchase Order Seller shall promptly commence manufacture of [***] units of Product
in such dosage strengths as requested by Purchaser (the “New Manufactured Lots”). Seller
shall promptly notify Purchaser when it commences manufacture of the New Manufactured Lots
and provide Purchaser with the lot numbers for all units of Product in the New Manufactured
Lots. If, prior to delivery to Purchaser, a portion of the New Manufactured Lots possess
less than [***] of expiry dating remaining on such Products, Purchaser shall reimburse
Seller [***] for each unit of Product in the New Manufactured Lots that possess less than
[***] of expiry dating.”

5. Amendment of Section 5.6.1 of the Agreement.

Section 5.6.1 of the Agreement is hereby deleted in its entirety and replaced with the following
new section 5.6.1:

“5.6.1 Notwithstanding anything herein to the contrary or anything to the contrary in any
Purchase Order or Forecast, Seller shall not be obligated to supply Purchaser (regardless
of amounts ordered by Purchaser), more than the Maximum Annual Product Units and, if
applicable, the Quarterly Adjustment (as defined below) during a twelve month period
measured from the date of First Commercial Sale and on each anniversary of the First
Commercial Sale. Without limiting the generality of the foregoing, any Purchase Order or
Forecast submitted by Purchaser hereunder for more than the Maximum Annual Product Units
and, if applicable, the Quarterly Adjustment shall, to the extent of the excess, be deemed
rejected by Seller, unless expressly accepted by Seller in writing.

*** Certain confidential information contained in this document, marked with three asterisks, has been omitted
and filed separately with the
Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

2

 

     “As used herein, “Maximum Annual Product Units” shall mean:

     “For the first [***] following First Commercial Sale: [***] Units of Product,
to be delivered to Purchaser as follows: [***] following First Commercial Sale;
[***] following First Commercial Sale; and [***] following First Commercial Sale.

     “For each annual period commencing on the [***] anniversary and each
subsequent annual anniversary of the First Commercial Sale, [***] Units of Product,
to be delivered at the rate of [***] Units of Product per [***].

     “Subject to the foregoing provisions of this Section 5.6.1, commencing with the end of
the [***] calendar quarter following First Commercial Sale, in the event Amphastar sells
more than [***] Units of Product (including sales to Purchaser and any other Person) in any
calendar quarter, as measured by [***] or a comparable, independent third party reporting
agency, Amphastar shall, at Watson’s request, increase its supply of Product to Watson in
the immediately following calendar quarter by up to the same percentage increase (the
“Quarterly Adjustment”) by which Amphastar exceeded [***] total Units of Product sold;
provided that, Amphastar shall have no obligation to supply Watson in any calendar quarter
with any Product in excess of [***] of the total combined units of Product, Lovenox® brand
product, Authorized Generic Product and Competitive Product sold to Purchaser Customers
(collectively, the “Retail Market Sales”) in the immediately preceding calendar quarter.
For purposes of clarification and notwithstanding anything to the contrary, if at any time
the total of the Maximum Annual Product Units plus the then applicable Quarterly Adjustment
exceeds [***] of the Retail Market Sales in the immediate preceding calendar quarter (the
“Supply Limit”), Amphastar shall have no obligation to supply Purchaser with any Product in
excess of the Supply Limit.

     “From time to time, should Seller have additional manufacturing capacity to permit it
to supply Products in excess of the Supply Limit, Purchaser may request and Seller shall
reasonably consider Purchaser’s request to purchase additional Product quantities in excess
of the Supply Limit; provided that, neither party shall have any obligation to agree to any
increase of Product quantities in excess of the Supply Limit.”

6. Scope of Amendment. Except as expressly and specifically amended hereby, all other
provisions, terms and conditions of the Agreement shall remain unchanged and in full force and
effect.

7. Counterparts. This First Amendment may be executed in several counterparts, each of
which shall be deemed and original, but all of which together shall constitute one

*** Certain confidential information contained in this document, marked with three asterisks,
has been omitted and filed separately with the Securities
and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

3

 

and the same instrument. Signatures delivered via facsimile or other electronic means shall have
the full force of an original signature.

8. Definitions. Unless otherwise defined herein, capitalized terms shall have the meanings
as defined in the Agreement.

IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute this
First Amendment as of the date first written above.

	 	 	 	 	 	 	 
	 	 	AMPHASTAR PHARMACEUTICALS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ John Weber	 	 
	 
	 	
 
	 	 
	 

	 	Name:
	 	John Weber	 	 
	 

	 	Title:
	 	C.F.O.	 	 
	 
	 	 	 	 	 	 
	 	 	ANDRX PHARMACEUTICALS, INC.,	 	 
	 	 	d/b/a WATSON LABORATORIES — FLORIDA	 	 
	 
	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Thomas R. Russillo	 	 
	 
	 	
 
	 	 
	 

	 	Name:
	 	Thomas R Russillo	 	 
	 

	 	Title:
	 	EVP and President, Generics Division	 	 

*** Certain confidential information contained in this document, marked with three asterisks, has been omitted and filed separately with the Securities and
Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}]]